Ipca Labs enters into technology transfer agreement with Omexa Formulary
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-03-29 09:53 GMT | Update On 2024-03-29 09:57 GMT
Advertisement
Mumbai: lpca Laboratories Ltd. has entered into a Technology Transfer Agreement with Omexa Formulary Pvt. Ltd. for a biosimilar clone, process development and knowledge transfer for the global market.
Under this Agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market a anti-cancer biosimilar for global market.
This Agreement shall enable Omexa to develop this anti-cancer biosimilar from early stage of development to clinical trials and subsequent commercial launch. This agreement will also strengthen Omexa's capability of biosimilar development.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.